20
Participants
Start Date
April 9, 2022
Primary Completion Date
April 25, 2022
Study Completion Date
April 25, 2022
Tachipirina® 120 mg/5 mL oral suspension, new flavour
A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
CROSS Research S.A. - Phase I Unit,, Arzo
Cross S.A.
INDUSTRY
Aziende Chimiche Riunite Angelini Francesco S.p.A
INDUSTRY